NCT03333590View on ClinicalTrials.gov

Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

November 6, 2017

Primary Completion Date

November 4, 2020

Study Completion Date

December 31, 2023

Conditions
Duchenne Muscular Dystrophy
Interventions
BIOLOGICAL

rAAVrh74.MCK.GALGT2

Adeno-associated virus serotype rh74 carrying the GALGT2 gene under the control of a MCK promoter (rAAVrh74.MCK.GALGT2) will be delivered one time to each of the lower limbs through the femoral artery using an intravascular limb infusion technique (ILI)

Trial Locations (1)

43205

Nationwide Children's Hospital, Columbus

All Listed Sponsors
lead

Kevin Flanigan

OTHER

NCT03333590 - Gene Transfer Clinical Trial to Deliver rAAVrh74.MCK.GALGT2 for Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter